A-Alpha Bio
A-Alpha Bio develops biotechnology platforms that use synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Its AlphaSeq platform enables rapid, quantitative measurement of millions of protein binding affinities, while AlphaBind predicts binding strength from sequence using a large protein interaction database. The company partners with pharmaceutical organizations and runs in-house therapeutic programs to support the discovery and development of novel medicines.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology Research
- Founded
- 2017
- Type
- Corporation Seattle business license
- Employees
- 50
- Registered name
- A Alpha Bio Inc Seattle business license
- Stage
- Series A
- Members see funding amounts. .
- Founders
- David Younger, PhD, Randolph Lopez, PhD
Is this your organization? Claim it
Harell Data founded by Harlan Robins raises $15M to let data owners securely monetize AI training
Harlan Robins, co-founder and former CSO of Adaptive Biotechnologies, launched Harell Data with $15 million in funding to let proprietary data owners securely host datasets for AI model training and receive direct revenue shares instead of waiting for downstream royalties.
Harell Data Raises $15M to Reward Data Generators and Speed AI Drug Discovery, Founder Harlan Robins Launches New Cloud Service
Harell Data, founded by Harlan Robins, raised $15 million to build a cloud platform that better rewards data generators and accelerates AI-driven drug discovery by hosting proprietary, well-curated datasets and secure GPU compute. The service partners with CoreWeave and initial data contributors like A-Alpha Bio to provide datasets for model builders while creating revenue-sharing incentives for those who produce the data.
Ally.io raises $50M Series C, bringing total funding to $76M; investors include Accel, Addition, GreenOaks
Ally.io, a Seattle-based company led by co-founder & CEO Vetri Vellore, has raised $76M total with a $50M Series C as its most recent round in February 2021, backed by investors including Accel, Addition, and GreenOaks.
People
-
David Younger Executive Officer, Director, Chief Executive Officer & Co-Founder
-
Randolph Lopez Chief Technology Officer & Co-Founder
Online
Questions about A-Alpha Bio
What is A-Alpha Bio?
A-Alpha Bio is a biotechnology startup based in Seattle that uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. The company partners with pharmaceutical organizations and runs in-house therapeutic programs to support medicine discovery and development.
What is A-Alpha Bio known for?
A-Alpha Bio develops AlphaSeq, a platform for quantitative measurement of protein binding affinities, and AlphaBind, which predicts binding strength from sequence using a protein interaction database.
Who are the people behind A-Alpha Bio?
Seattle Flow lists David Younger (Executive Officer, Director, Chief Executive Officer & Co-Founder) and Randolph Lopez (Chief Technology Officer & Co-Founder) at A-Alpha Bio.
Who invested in A-Alpha Bio, and how much has it raised?
Members of Seattle Flow see A-Alpha Bio's funding rounds, amounts and investors on its Funding tab. Joining is free.
Where is A-Alpha Bio based?
A-Alpha Bio is based in Seattle.
When was A-Alpha Bio founded?
A-Alpha Bio was founded in 2017.